FDA Brief

Warning letters Drugs

FDA warning letter to

Amazon.com, Inc.

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warned Amazon that three creams sold and shipped through Fulfillment by Amazon are unapproved new drugs for phimosis and balanitis.

What happened

In May 2026, FDA bought three products on www.amazon.com — "Vajraang Phimosis Mini Combo," "Penile Heal Cream" and "Beilloso Balanitis Relief Cream" — and reviewed their labeling. FDA says Amazon shipped each one directly to individual U.S. consumers on behalf of third parties through its Fulfillment by Amazon service. The labels claim to treat phimosis, paraphimosis and balanitis, which makes the products drugs, and FDA found no approved application for any of them.

What FDA found

  1. The labels say the creams treat phimosis, paraphimosis and balanitis, so they are drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The creams are not generally recognized as safe and effective for what their labels say, so they count as new drugs.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. No FDA-approved application is in effect for these products, so selling them across state lines is illegal.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. The Beilloso cream claims relief from balanitis, which goes beyond the allowed over-the-counter antifungal claims and does not fit any FDA final order.

    Section 505G of the FD&C Act

What FDA wants

FDA tells Amazon to find the root causes, put corrective and preventive measures in place, and send a written response with the steps taken and supporting documents. The response is due within 15 business days of receiving the letter, marked with reference number 728814.

Who should pay attention

  • online marketplaces that store, pack and ship third-party health products
  • sellers of creams making claims about phimosis or balanitis
  • brands relying on marketplace fulfillment for drug-labeled items

This is a summary. Read the original letter on fda.gov.

Amazon.com, Inc.'s FDA history

  1. Amazon.com, Inc.

    FDA warns Amazon over nine unapproved drugs sold on its website for genital herpes and STI symptoms.

    High risk
  2. Amazon.com, Inc.

    Nonprescription/OTC

  3. Amazon.com, Inc.

    Unapproved New Drugs/Misbranded

  4. Amazon.com, Inc.

    Finished Pharmaceuticals/Unapproved New Drugs

  5. Amazon.com, Inc.

    Finished Pharmaceuticals/Unapproved New Drug/Misbranded

  6. Amazon.com, Inc.

    Unapproved New Drugs/Misbranded

  7. Amazon.com, Inc

    Unapproved New Drugs/Misbranded

  8. Amazon.com, Inc.

    Finished Pharmaceuticals/Unapproved New Drug/Misbranded

  9. Amazon.com, Inc.

    Finished Pharmaceuticals/Unapproved New Drug

Full company page

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk